Prodia Group's PRDL Shares Surge 35% on IDX Debut

Jakarta, CNBC Indonesia – Healthcare sector issuer Prodia Group, PT Prodia Diagnostic Line Tbk (PRDL), has officially listed its shares on the Indonesia Stock Exchange (IDX). The company released 522.9 million new shares, equivalent to 30% of its fully paid-up capital, at Rp120 per share.

As a result, the Prodia Group subsidiary will raise fresh funds of Rp62.75 billion. In its market debut, PRDL shares immediately recorded a gain of 35%, or 42 points, from the offer price to a level of Rp162 per share.

Chief Executive Cristina Sandjaja said the company sees substantial growth opportunities, particularly in primary healthcare facilities that have not yet been fully reached.

“With our superior product quality, large production capacity, extensive distribution network and the high local content (TKDN) value of our products, we are optimistic that we can expand market penetration while becoming a strategic partner of the government in strengthening national healthcare services,” she said in Jakarta on Thursday (9/7/2026).

Of the total funds raised, around Rp35.67 billion will be used to repay the principal on loans from PT Bank Central Asia Tbk (BCA) and PT Bank Pan Indonesia Tbk (Panin Bank).

In terms of financial performance, PRDL’s net profit reached around Rp35.8 billion in 2023, then fell sharply to Rp10 billion in 2024, before recovering to around Rp17 billion in 2025.

PRDL is a company engaged in the manufacture and processing of medical devices related to diagnostics, or in vitro diagnostics (IVD). The company operates production facilities in the Jababeka III Industrial Estate, Cikarang, West Java.